Mentari Therapeutics, Inc. announced a $200 million private placement of common stock and pre-funded warrants to healthcare investors including Fairmount, Venrock, and Blackstone. This additional financing, occurring concurrently with a previously announced $290 million private placement, is intended to most likely extend Mentari's cash runway into 2029 to support clinical development of its migraine prevention pipeline. InMed Pharmaceuticals Inc. is a biotechnology company that develops therapies for migraine prevention.

InMed Pharmaceuticals Inc. entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics, Inc. to clarify transaction sequencing, including a name change to Mentari Therapeutics, Inc. and redomestication to Nevada. The amendment introduces a Company PIPE Amendment to facilitate potential pre-closing private placement financing and clarifies tax treatment as an integrated reorganization. InMed Pharmaceuticals Inc. is a biopharmaceutical company focused on developing medicinal plant-derived cannabinoid-based therapeutics.

InMed Pharmaceuticals Inc. received notice from Nasdaq on June 3, 2026, that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company had previously been notified of non-compliance on March 27, 2026, after its shares closed below $1.00 for 30 consecutive trading days. InMed Pharmaceuticals is a pharmaceutical company that develops and commercializes medical treatments.